NOV 30, 2015 1:10 PM PST

New Test Finds Hidden Pancreatic Cancer Cells, Improves Treatment

WRITTEN BY: Xuan Pham
Pancreatic cancer has one of the worst mortality rates of all cancer types, largely because the cancer spreads rapidly and is seldom detected in its early stages. But researchers at the University of Chicago have found that sampling blood from the portal vein is more sensitive at detecting the cancer’s presence. This method may help doctors to diagnose pancreatic cancer earlier, providing a means to increase prognosis for this disease.
 
Blood taken from the portal vein detects higher tumor cell counts.

In the recent years, scientists have known that tumors can shed cancerous cells from the primary site into the patient’s bloodstream. They call these circulating tumor cells (CTCs), and have leveraged CTC’s presence to create detection methods for a wide range of cancers. Currently, the detection method for pancreatic cancer relies on blood taken from traditional arm venipunctures. However, researchers at the University of Chicago have challenged the sensitivity of this method.

The researchers reasoned that because of the large and irregular shape of CTCs, these cells can get trapped in small vessels before showing up in the bloodstream. So they devised a collection method where blood was taken from the portal vein, the main vessel that drains blood from the gastrointestinal tract and spleen to the liver. Compared to blood taken from the arm, portal vein blood showed much higher sensitivity at detecting tumor cell counts.

"This is a novel and far more sensitive way to acquire, enumerate, and characterize CTCs from pancreatobiliary and other gastrointestinal cancers in this setting.” Dr. Irving Waxman, senior study author.

 In 18 patients with suspected tumors in the pancreas and bile ducts, portal vein sampling detected CTCs for all 100% of patients. In contrast, tumor cells were only detected for 22% of patients with the traditional peripheral blood sampling method. Additionally, they found that the portal vein contained an abundance of CTCs for all cancer stages, including the hard-to-detect early stages. For every 7.5 milliliters of blood, more than 100 tumor cells were detected with portal vein blood samples, compared ~ 1 tumor cell for peripheral blood samples.

This new sampling method will be especially beneficial for early diagnosis of pancreatic cancer. According to the National Cancer Institute, the five-year survival rate for pancreatic cancer is only 7.2%. The disease is so deadly because signs and symptoms don’t appear until the cancer is quite advanced. By such point, the cancer has likely metastasized and surgical removal is not effective. However, with this method, the cancer can be detected early enough where removal is still possible.

"In the setting of localized cancer where these findings are most applicable, the additional information of portal vein CTC number and their molecular characterization may help predict who will benefit from aggressive therapy before surgery, who is most at risk for a recurrence after the operation, and even who will not benefit from surgery at all." Dr. Daniel Catenacci, co-first author of the study.

Watch the video to learn more about pancreatic cancer.
 

Sources: Gastroenterology, Science Daily
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
AUG 06, 2020
Clinical & Molecular DX
Gut Feeling: Spotting the Early Signs of Gastric Cancer
AUG 06, 2020
Gut Feeling: Spotting the Early Signs of Gastric Cancer
In a study published in Science Advances, scientists propose a new method for diagnosing gastric cancer, the third leadi ...
SEP 03, 2020
Clinical & Molecular DX
Tiny Diagnostic Robot Tank Explores the Colon
SEP 03, 2020
Tiny Diagnostic Robot Tank Explores the Colon
The colon, also known as the large intestine, is where the final stages of digestion happen. Here, water, salts, and rem ...
SEP 24, 2020
Clinical & Molecular DX
2-In-1: Stroke Scans Also Diagnose COVID
SEP 24, 2020
2-In-1: Stroke Scans Also Diagnose COVID
King’s College London researchers took a closer look at emergency room CT scans of patients suspected of having a ...
OCT 06, 2020
Clinical & Molecular DX
Radioactive Tracer Shines the Floodlights on Inflammation
OCT 06, 2020
Radioactive Tracer Shines the Floodlights on Inflammation
A patient checks into the hospital with difficulty breathing. Is inflammation to blame? How can physicians visualize are ...
OCT 29, 2020
Clinical & Molecular DX
More Frequent Trips to the Pediatrician Linked to a Future Autism Diagnosis
OCT 29, 2020
More Frequent Trips to the Pediatrician Linked to a Future Autism Diagnosis
 
NOV 03, 2020
Clinical & Molecular DX
"Hello? It's Me, the Coronavirus."
NOV 03, 2020
"Hello? It's Me, the Coronavirus."
Researchers at MIT have discovered an unlikely way of discerning those with COVID-19 from healthy individuals — si ...
Loading Comments...